NCT07804641CompletedPhase 2
Safety and Efficacy of the Combination Therapy of Fucoidan / Fucoxanthin / L-carnitine in Patients With Diabetic Nephropathy.
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of fucoidan/fucoxanthin/L-carnitine combinaed therapy in patients with diabetic kidney disease. Participants were randomly assigned in a 1:1 ratio to either the Treatment Group or the Control Group. The primary objective is to investigate whether fucoidan/fucoxanthin/L-carnitine/Zinc yeast combinaed therapy can significantly improve albuminuria or renal function after a treatment period of 12 weeks. Secondary outcomes include evaluating the safety profile and potential side effects of the intervention. It is hypothesized that the intervention will show a beneficial effect on albuminuria compared to the control group. in patients withdiabetic kidney disease.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- First submitted
- 31 Aug 2026
- Start date
- 6 Nov 2024
- Primary completion date
- 5 Nov 2025
- Lead sponsor
- Taipei Medical University WanFang Hospital
- Diseases
- Chronic kidney disease
- NCT number
- NCT07804641
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 63
- From 6 Nov 2024 to the primary completion date, 5 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Medication non-compliance, defined as completing less than 50% of the prescribed formula (FFL) treatment.
Other illness
- Absence of regular treatment for diabetes mellitus.
Lab values
- Loss to follow-up, defined as failure to complete all laboratory tests required for outcome assessment.
Age
- Age younger than 20 years.
Other
- Inability to understand or provide written informed consent.
- Newly diagnosed glomerulonephritis during the study period.
Who the study is looking for
- Documented glycated hemoglobin (HbA1c) \> 6.5% with current use of anti-diabetic medication.
- A urine albumin-to-creatinine ratio (UACR) greater than 30 mcg/mg.
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wanfang Hospital, Taipei Medical Univeristy Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.